Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
NPJ Breast Cancer. 2023 Apr 12;9(1):24.
doi: 10.1038/s41523-023-00532-3.
1 Department of Surgery, Oncology and Gastroenterology, University of Padova, via Giustiniani 2, 35128, Padova, Italy. [email protected].
2 Oncology 2, Veneto Institute of Oncology IOV-IRCCS, via Gattamelata 64, 35128, Padova, Italy. [email protected].
3 Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS, via Giovanni Amendola 2, 42122, Reggio Emilia, Italy.
4 Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy.
5 Clinical Oncology, Department of Translational Medicine and for Romagna, S. Anna University Hospital, via Aldo Moro 8, 44124, Ferrara, Italy.
6 Department of Medical and Surgical Sciences for Children & Adults, University of Modena, via del Pozzo, 71, 41124, Modena, Italy.
7 Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo, 71, 41124, Modena, Italy.
8 Veneto Oncology Network, via Gattamelata 64, 35128, Padova, Italy.
9 Department of Surgery, Oncology and Gastroenterology, University of Padova, via Giustiniani 2, 35128, Padova, Italy.
10 Oncology 2, Veneto Institute of Oncology IOV-IRCCS, via Gattamelata 64, 35128, Padova, Italy.